Greenwich LifeSciences Inc. (GLSI): Price and Financial Metrics
GET POWR RATINGS... FREE!
GLSI Stock Price Chart Interactive Chart >
GLSI Price/Volume Stats
| Current price | $38.96 | 52-week high | $158.07 |
| Prev. close | $39.44 | 52-week low | $3.26 |
| Day low | $38.65 | Volume | 93,500 |
| Day high | $40.40 | Avg. volume | 459,246 |
| 50-day MA | $36.90 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 502.58M |
Greenwich LifeSciences Inc. (GLSI) Company Bio
Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.
Latest GLSI News From Around the Web
Below are the latest news stories about Greenwich LifeSciences Inc that investors may wish to consider to help them evaluate GLSI as an investment opportunity.
Greenwich LifeSciences Set to Join Russell 2000® IndexGreenwich LifeSciences Set to Join Russell 2000® Index |
Greenwich LifeSciences' Breast Cancer Vaccine Unveils Five Year Data, Confirming to Prevent Metastatic Breast Cancer RecurrenceGreenwich LifeSciences Inc (NASDAQ: GLSI) presented five-year data from Phase 2 breast cancer clinical trial evaluating GP2 immunotherapy in patients who have previously undergone surgery. Data were presented at the 2021 American Society of Clinical Oncology Annual Meeting. Final safety conclusions are that GP2 immunotherapy is well tolerated and that no serious adverse events related to GP2 immunotherapy were reported over the full five-year follow-up period. Data shows 100% disease-free surviv |
Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming that GP2 Treatment to Prevent Metastatic Breast Cancer Recurrence is Well ToleratedGreenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming GP2 Treatment is Well Tolerated |
1 Drug, 1 Mission: What Should Investors Expect for Greenwich Life Sciences?The top-performing IPO of 2020 is a high-risk, high-reward opportunity, with one drug in its pipeline and one disease in its sights. Is it worth investing in now? |
Today’s Biggest Pre-Market Movers: 10 Top Gainers and Losers on Thursday MorningIt's Thursday morning and investors keeping track of the pre-market will want to make sure they check out this list of movers! |
GLSI Price Returns
| 1-mo | 18.24% |
| 3-mo | 36.22% |
| 6-mo | -26.35% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 6.83% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...